Patent intelligence · US
US 11969424
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
Patent details — US 11969424
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 30, 2024
- Expiration
- Apr 25, 2044
- Applicant
- TENAX THERAPEUTICS, INC.
- Claims
- 20
- CPC classes
- A61K, A61K31/216, A61K31/41, A61K31/495
Quick answer
US 11969424 (Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)) is held by TENAX THERAPEUTICS, INC.. Status: granted. Granted Apr 30, 2024. Expires Apr 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TENAX THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/216, A61K31/41, A61K31/495, A61K31/50, A61K31/502
More from TENAX THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 11701355
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11607412
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11213524
Pharmaceutical compositions for subcutaneous administration of levosimendan
granted
Frequently asked questions
What is US patent 11969424?
US 11969424 (Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)) is held by TENAX THERAPEUTICS, INC.. Status: granted. Granted Apr 30, 2024. Expires Apr 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11969424?
TENAX THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11969424 expire?
Our index shows an expiration date of Apr 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.